Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, for what reason the MHRA has not yet decided whether to approve Ivermectin as a treatment for covid-19; and whether the approval process for that treatment differs to that relating to Sotrovimab.
For a product to be granted a licensing authorisation, a company must apply to the Medicines and Healthcare products Regulatory Agency (MHRA) for authorisation. The MHRA has not received an application for use of Ivermectin in the treatment of patients with COVID-19. If received, the application will undergo a safety, efficacy and quality review, including consultation with Commission on Human Medicines.